Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund

CONCLUSION: Nivolumab as a single agent is fairly active in a cohort of unselected pretreated pleural mesothelioma patients. Further investigations on clinical and translational factors are needed to define which patient might benefit most from nivolumab treatment in pleural mesothelioma.PMID:38372045 | DOI:10.1177/03008916241229287

Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Luigi Cerbone Sara Delfanti Stefania Crivellari Antonina Maria De Angelis Laura Mazzeo Claudia Proto Mario Occhipinti Giuseppe Lo Russo Chiara Dellepiane Federica Biello Irene Alabiso Francesco Verderame Roberta Gauna Irene De Simone Federica Cuppone Sand Source Type: research